Trabectedin and Durvalumab Combination is Feasible - and Active in Relapsing Ovarian Cancer. Digklia A, Coukos G, Homicsko K. Clin Cancer Res 2022 Feb 17. pii: 681578. doi: 10.1158/1078-0432.CCR-21-4592.

Read + Share

Amedeo Smart

Independent Medical Education

Digklia A, Coukos G, Homicsko K. Trabectedin and Durvalumab Combination is Feasible - and Active in Relapsing Ovarian Cancer. Clin Cancer Res 2022 Feb 17. pii: 681578. doi: 10.1158/1078-0432.CCR-21-4592.
PMID: 35176150